Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has prepared and tested prodrugs of N4-hydroxycytidine (NHC) that are reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Research at Umecrine AB has led to the identification of a 3α-substituted 3β-hydroxy 17-oximated androstane compound acting as a GABA-A receptor antagonist.
Terminal nucleotidyltransferase 4B (TENT4B; PAPD5) inhibitors have been described in a Childrens Medical Center Corp. patent. As such, they are reported to be useful for the treatment of cancer, osteoarthritis, macular degeneration, hepatitis B, pulmonary fibrosis, diabetes, pontocerebellar hypoplasia and cardiovascular disorders, among others.
Researchers at Abbvie Inc. and Calico Life Sciences LLC have described protein tyrosine phosphatase inhibitors, particularly tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) and/or PTPN1 (PTP-1B), reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
Qilu Regor Therapeutics Inc. has divulged protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of sepsis, cancer, bacterial, viral infections, inflammatory disorders, autoimmune diseases and metabolic diseases.
Insilico Medicine IP Ltd. has identified small-molecule inhibitors of ubiquitin carboxyl-terminal hydrolase 1 (USP1) reported to be useful for the treatment of cancer.
RSS